BIOMARIN PHARMACEUTICAL INC

Form 4

January 03, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287 January 31,

2005

0.5

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Expires: Estimated average

OMB APPROVAL

burden hours per

response...

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

(Print or Type Res	ponses)					
1. Name and Address of Reporting Person * ASELAGE STEVE			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 10/31/2007	Director 10% Owner _X_ Officer (give title Other (specify below) SVP, Global Commercial Dev		
NOVATO, CA	(Street) A 94949		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acc	quired, Disposed of, or Beneficially Owne		

(City)	(State)	(Zip) Tab	le I - No	n-I	Derivative	Secu	rities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8		4. Securi nor Dispos (Instr. 3,	sed of	` '	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/31/2007(1)		P	V	2,139	A	\$ 6.919	7,034	D	
Common Stock	01/02/2008(2)	01/02/2008	M		5,000	A	\$ 7.16	12,034	D	
Common Stock	01/02/2008(2)	01/02/2008	S		200	D	\$ 35.97	11,834	D	
Common Stock	01/02/2008(2)	01/02/2008	S		300	D	\$ 35.9701	11,534	D	
	01/02/2008(2)	01/02/2008	S		200	D	\$ 35.98	11,334	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	01/02/2008(2)	01/02/2008	S	300	D	\$ 35.99	11,034	D
Common Stock	01/02/2008(2)	01/02/2008	S	400	D	\$ 36.11	10,634	D
Common Stock	01/02/2008(2)	01/02/2008	S	100	D	\$ 36.12	10,534	D
Common Stock	01/02/2008(2)	01/02/2008	S	500	D	\$ 36.1301	10,034	D
Common Stock	01/02/2008(2)	01/02/2008	S	500	D	\$ 36.1801	9,534	D
Common Stock	01/02/2008(2)	01/02/2008	S	260	D	\$ 36.31	9,274	D
Common Stock	01/02/2008(2)	01/02/2008	S	240	D	\$ 36.32	9,034	D
Common Stock	01/02/2008(2)	01/02/2008	S	500	D	\$ 36.48	8,534	D
Common Stock	01/02/2008(2)	01/02/2008	S	500	D	\$ 35.28	8,034	D
Common Stock	01/02/2008(2)	01/02/2008	S	300	D	\$ 36.03	7,734	D
Common Stock	01/02/2008(2)	01/02/2008	S	200	D	\$ 36.04	7,534	D
Common Stock	01/02/2008(2)	01/02/2008	S	100	D	\$ 36.3025	7,434	D
Common Stock	01/02/2008(2)	01/02/2008	S	400	D	\$ 36.31	7,034	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

 $\label{thm:convertible} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired		
	Derivative				(A) or		
	Security				Disposed of		
					(D)		

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

(Instr. 3, 4, and 5)

Code V (A) (D) Date Exercisable Expiration Title Amount

or Number

of Shares

Stock

Option (right to buy)

\$ 7.16 01/02/2008(2)

01/02/2008 M 5,000 07/01/2006(3) 06/30/2015

Common 5,000 Stock

Reporting Owners

Relationships Reporting Owner Name / Address

> 10% Owner Officer Other

ASELAGE STEVE C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE **NOVATO, CA 94949**

SVP, Global Commercial Dev

Signatures

/s/ G. Eric Davis, 01/03/2008 Attorney-in-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to the Employee Stock Purchase Plan.
- (2) Transaction made pursuant to a Rule 10b5-1 Trading Plan.
- (3) Original option grant vested 12/36ths on 7/1/2006 and 1/36th on the 1st of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3